Outlook Therapeutics, Inc. Company Profile, Contacts & Intelligence

Outlook Therapeutics, Inc. Overview

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, including wet AMD. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics is working to initiate its commercial launch of LYTENAVA™ (bevacizumab gamma) in the EU and the UK as a treatment for wet AMD, expected in the second quarter of calendar 2025. In the United States, ONS-5010/LYTENAVA™ is investigational, and a BLA has been resubmitted to the FDA in the United States. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.

Headquarters

Cranbury, New Jersey, United States

Website

www.outlooktherapeutics.com

Industry

Biotechnology Research

Founded

2011

Stock Symbol

OTLK

NAICS

Research and Development in Biotechnology (except Nanobiotechnology)

Outlook Therapeutics, Inc. Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

Outlook Therapeutics, Inc. People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

Compare Similar Companies to Outlook Therapeutics, Inc.

Explore companies in related markets and compare their industry and employee estimates.